GenScript Biotech and NSG Bio Form Strategic Partnership to Accelerate Biotech Innovation in Singapore
核心洞察
GenScript Biotech Corporation (搜索) and NSG Bio (搜索) have established a strategic partnership to provide preferential rates and technical expertise to biotech startups in Singapore, enhancing innovation and accelerating commercialization.
NSG Bio (搜索), founded in 2019, has supported over 50 resident companies across health, biomedical, and agrifood sectors, offering Singapore's largest co-working biotech laboratory and extensive industry networks.
The collaboration aims to strengthen Singapore's position as a global biomedical innovation hub by enabling emerging biotech companies to access cutting-edge scientific capabilities while allocating more resources toward breakthrough research.
GenScript Biotech Corporation (搜索), a global biotechnology research services leader, and NSG Bio (搜索), Singapore's premier biotech incubator, announced a strategic partnership aimed at accelerating innovation within Singapore's biotechnology ecosystem.
Under the new agreement, GenScript will offer exclusive preferential pricing and technical guidance from its experienced scientists across its extensive range of biotechnology services and products to companies within the NSG Bio (搜索) incubator. This initiative is designed to empower startups and emerging biotech firms by providing easier access to advanced technologies and services.
"We are excited to partner with NSG Bio (搜索) to bolster Singapore's dynamic biotechnology ecosystem," stated Dr. Janice Jin, President of GenScript Asia Pacific. "By extending preferential pricing and technical expertise to residents of NSG Bio, we aim to foster greater innovation among emerging biotechnology companies, allowing them to allocate more resources toward achieving scientific breakthroughs and market readiness."
Accelerating the Research-to-Market Pipeline
The partnership specifically targets one of the most significant challenges facing biotech startups: the high cost and technical complexity of transitioning from research to commercialization. By reducing financial barriers and providing specialized expertise, the collaboration aims to shorten development timelines and increase success rates for innovative biotech products and services.
Since its founding in 2019, NSG Bio (搜索) has established itself as a crucial support system for biotech innovators in Singapore. The incubator specializes in several cutting-edge areas including precision medicine (搜索), nucleic acid technologies, AI-driven drug discovery (搜索), and synthetic biology (搜索). With Singapore's largest co-working biotech laboratory and office spaces spanning 70,000 square feet in the Biopolis and Science Park areas, NSG Bio has supported over 50 resident companies to date.
Ms. Daphne Teo, Chairwoman of the Board & Founder of NSG Bio (搜索), emphasized the strategic importance of the partnership: "NSG Bio is committed to fostering a thriving and world-class biotechnology ecosystem in Singapore. Our partnership with GenScript represents a significant step forward in enabling our resident companies to access cutting-edge scientific capabilities and industry expertise. By deepening collaboration between leading global service providers and local biotech innovators, we are helping to catalyze impactful scientific advancements and reinforce Singapore's position as a global hub for biomedical innovation."
Strengthening Singapore's Biotech Ecosystem
The collaboration comes at a strategic time for Singapore's biotechnology sector, which has seen substantial growth in recent years. The city-state has actively positioned itself as a biomedical hub in Asia, with government initiatives supporting research infrastructure and talent development.
GenScript brings considerable resources to the partnership. Founded in 2002 in New Jersey, the company has grown to include over 5,500 employees serving more than 200,000 customers across over 100 countries and regions. Its comprehensive service offerings include gene synthesis, protein production, antibody development, and other critical research tools that form the building blocks of biotechnology innovation.
For NSG Bio (搜索) residents, the partnership provides access not only to GenScript's technical capabilities but also to its global network and industry expertise. This combination of resources is particularly valuable for companies working in specialized fields like precision medicine (搜索) and synthetic biology (搜索), where technical challenges can be significant barriers to progress.
Focus on Multiple Biotechnology Sectors
The partnership will support innovation across multiple biotechnology sectors, including health, biomedical, agrifood, and industrial applications. This broad approach reflects the diverse nature of NSG Bio (搜索)'s resident companies and the wide-ranging potential of biotechnology to address global challenges.
Both organizations emphasized that this collaboration represents a mutual commitment to empowering biotechnology entrepreneurs and developing a vibrant and resilient biotechnology ecosystem in Singapore. By combining GenScript's global reach and technical expertise with NSG Bio (搜索)'s local knowledge and supportive infrastructure, the partnership aims to create a more favorable environment for biotechnology innovation in the region.
The arrangement is expected to benefit not only current NSG Bio (搜索) residents but also attract new biotech startups to the incubator, further strengthening Singapore's position as a leading biotechnology hub in Asia and globally.